# Seamless Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/seamless-therapeutics

- Industry: Biotechnology
- Headquarters: Dresden, Germany
- Website: www.seamlesstx.com
- Total disclosed funding: $13M
- Latest round: Seed (Jul 21, 2022)
- Investors on record: 2

## About

Based in Dresden, Germany, and founded in 2022 by cofounders Prof. Dr. Frank Buchholz, and Anne-K. Heninger, and Felix Lansing, Seamless Therapeutics GmbH, aka Seamless Therapeutics, provides a gene editing platform to transform the treatment of severe diseases. In July 2022, Seamless Therapeutics raised USD 12.5 million in seed funding, co-led by new investors Wellington Partners and Forbion.

The company's recombinase platform allows molecular biology tools to unlock the full potential of gene editing, permitting the targeting of any place in the genome to restore health in patients with severe conditions.

## Funding rounds

- Seed, Jul 21, 2022, $13M — Wellington Partners, Forbion

## Investors

- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Seed
- Forbion (https://capitalatlas.ai/funds/forbion) — Seed